The FDA enabled reproductive health providers to prescribe mifepristone, the abortion medication, via telemedicine — at least through the duration of the pandemic. The FDA approved lifting the requirement of in-person dispensing of mifepristone, since the COVID-19 pandemic presents additional COVID-related risks to patients and healthcare personnel when patients visit a clinic solely to receive a prescription.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.